Economic considerations related to providing adequate pain relief for women in labour: comparison of epidural and intravenous analgesia.

abstract：:Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

journal_title：PharmacoEconomics

authors： Mauskopf J,Annemans L,Hill AM,Smets E

更新日期：2010-01-01 00:00:00

abstract：:The progressive increase in the prevalence of obesity and aging in the population is resulting in increased healthcare and disability spending. The burden of obesity is particularly relevant in old age, due to accumulating co-morbidities and changes in body composition. Sarcopenic obesity, a mix of over- and under-nut...

journal_title：PharmacoEconomics

authors： Corica F,Bianchi G,Corsonello A,Mazzella N,Lattanzio F,Marchesini G

更新日期：2015-07-01 00:00:00

abstract：:The objective of this study was to demonstrate the cost effectiveness of long term maintenance treatment with citalopram versus standard therapy (defined as short term antidepressant treatment) in patients with major depression in Germany. We chose doxepin, amitriptyline and trimipramine as standard therapy because th...

journal_title：PharmacoEconomics

authors： Nuijten MJ,Hardens M,Souêtre E

更新日期：1995-08-01 00:00:00

abstract：:This article explores the need to perform pharmacoeconomic evaluations of herbal medicines and assesses the extent to which this approach has been applied so far to these products. There seems to be no compelling need for pharmacoeconomic analyses of herbal over-the-counter medicines, but such analyses are certainly w...

journal_title：PharmacoEconomics

authors： De Smet PA,Bonsel G,Van der Kuy A,Hekster YA,Pronk MH,Brorens MJ,Lockefeer JH,Nuijten MJ

更新日期：2000-07-01 00:00:00

abstract：BACKGROUND:Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high. Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in which treatment is intensified when...

journal_title：PharmacoEconomics

authors： Rutten-van Mölken MP,Goossens LM

更新日期：2012-04-01 00:00:00

abstract：:Hepatitis B virus (HBV) infection is an important public health problem all over the world. Vaccination is one way to prevent it, and several strategies can be used depending on endemicity, the main pattern of HBV transmission and the demographic structure of the population. In this study, an economic comparison of 3 ...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Garuz R,Rovira J,Antón F,Trinxet C,Navas E,Salleras L

更新日期：1995-05-01 00:00:00

abstract：OBJECTIVES:Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. However, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in certain contexts, there exists no recent description of the general state ...

journal_title：PharmacoEconomics

authors： Soekhai V,de Bekker-Grob EW,Ellis AR,Vass CM

更新日期：2019-02-01 00:00:00

abstract：:Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

journal_title：PharmacoEconomics

authors： Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Healthcare resource use data were collected for 1 year as part of the CAESAR (Canada, Australia, Europe, South Africa) clinical trial, which evaluated the effect of adding lamivudine to treatment regimens containing zidovudine in patients with HIV infection. This study showed that lamivudine-containing regim...

journal_title：PharmacoEconomics

authors： Lacey L,Mauskopf J,Lindrooth R,Pham S,Saag M,Sawyer W

更新日期：1999-01-01 00:00:00

abstract：OBJECTIVE:The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS:A sys...

journal_title：PharmacoEconomics

authors： Rodriguez-Martinez CE,Sossa-Briceño MP,Castro-Rodriguez JA

更新日期：2018-10-01 00:00:00

abstract：:We have defined the effect and acceptability of a locally developed general practice programme for the modification of prescribing. This voluntary programme consisted of prescription analysis and feedback, followed by visits from a pharmacist, a therapeutic bulletin on benzodiazepine prescribing, and use of a locally ...

journal_title：PharmacoEconomics

authors： Ferguson RI,Salmond CE,Maling TJ

更新日期：1995-06-01 00:00:00

abstract：:Constipation is one of the most common digestive complaints. It is a symptom, not a disease. The subjectivity that this involves means that assessments of clinical epidemiology, socioeconomic costs and pharmacotherapy are difficult, since there is no definition of 'normal' bowel habit. Although constipation can affect...

journal_title：PharmacoEconomics

authors： Passmore AP

更新日期：1995-01-01 00:00:00

abstract：:Proper economic evaluation involves comparative analysis of alternative courses of action in terms of both costs and outcome. This is difficult for general anaesthesia as there are few alternatives and measurement of outcome is difficult to define. All that is generally available is a cost description of different a...

journal_title：PharmacoEconomics

authors： Rhodes SP,Ridley S

更新日期：1993-02-01 00:00:00

abstract：:This study evaluated the cost utility of adding interferon-alpha 2b to conventional treatment in patients with multiple myeloma. It also provides a methodology for transforming complex quality-of-life profiles into a single index value on the conventional 0 to 1 quality-adjusted life-year scale (QALY). From 1990 to 19...

journal_title：PharmacoEconomics

authors： Nord E,Wisløff F,Hjorth M,Westin J

更新日期：1997-07-01 00:00:00

abstract：BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...

journal_title：PharmacoEconomics

authors： Petrou S,Rivero-Arias O,Dakin H,Longworth L,Oppe M,Froud R,Gray A

更新日期：2015-10-01 00:00:00

abstract：BACKGROUND:Health technology assessment has been increasingly used in China, having been legally mandated in 2019, to inform reimbursement decisions and price negotiations between the National Healthcare Security Administration and pharmaceutical companies around the price of new pharmaceuticals. The criteria currently...

journal_title：PharmacoEconomics

authors： Ochalek J,Wang H,Gu Y,Lomas J,Cutler H,Jin C

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:Given the association between CD4 cell counts and HIV-related morbidity/mortality, new antiretroviral therapies could potentially lower the direct costs of HIV care by raising CD4 cell counts. OBJECTIVES:To predict the effects of the ritonavir-boosted, HIV protease inhibitor (PI) darunavir on the direct cos...

journal_title：PharmacoEconomics

authors： Hill AM,Gebo K,Hemmett L,Löthgren M,Allegri G,Smets E

更新日期：2010-01-01 00:00:00

abstract：:Migraine headache is responsible for significantly more healthcare resource and lost labour costs than previously reported. Costs associated with migraine were assessed via a survey conducted in 940 patients, 70% of whom responded. All met the International Headache Society's diagnostic criteria for migraine and had ...

journal_title：PharmacoEconomics

authors： Osterhaus JT,Gutterman DL,Plachetka JR

更新日期：1992-07-01 00:00:00

abstract：:The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...

journal_title：PharmacoEconomics

authors： Payne K,Kozma CM,Lawrence BJ

更新日期：1996-07-01 00:00:00

abstract：OBJECTIVE:To compare the cost effectiveness of sequential intravenous (i.v.) to oral ciprofloxacin plus metronidazole (CIP/MTZ i.v./PO) with that of i.v. ciprofloxacin plus i.v. metronidazole (CIP/MTZ i.v.) and i.v. imipenem-cilastatin (IMI i.v.) in patients with intra-abdominal infections. DESIGN AND PARTICIPANTS:Pat...

journal_title：PharmacoEconomics

authors： Walters DJ,Solomkin JS,Paladino JA

更新日期：1999-11-01 00:00:00

abstract：:Peptic ulcer disease (PUD) is a common medical problem costing billions of dollars annually around the world. Since the availability of the first histamine H2-receptor antagonist, cimetidine, many economic analyses have been conducted to compare the impact of this drug class on resource consumption. H2-Antagonists h...

journal_title：PharmacoEconomics

authors： Tucker PP,Nash DB

更新日期：1994-04-01 00:00:00

abstract：BACKGROUND:Cost-effectiveness analyses worldwide assume that the price of any single drug increases with inflation. New guidance from the Pharmaceutical Management Agency in New Zealand suggests that, when it is known that a generic drug will be available in the near future, a best estimate of the lower price of the ge...

journal_title：PharmacoEconomics

authors： Hoyle M

更新日期：2008-01-01 00:00:00

abstract：:This paper analyses the 32 technology appraisals completed by the National Institute for Clinical Excellence (NICE) in the UK from its establishment to the end of January 2002. It looks at why technologies have been rejected, what has happened to products reviewed at launch, evidence of rationing on cost-effectiveness...

journal_title：PharmacoEconomics

authors： Towse A,Pritchard C

更新日期：2002-01-01 00:00:00

abstract：CONTEXT:This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required. METHODS:A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nomi...

journal_title：PharmacoEconomics

authors： Rogowski W,Payne K,Schnell-Inderst P,Manca A,Rochau U,Jahn B,Alagoz O,Leidl R,Siebert U

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Terkola R,Overton PM,Shalet N,Postma M

更新日期：2017-08-01 00:00:00

abstract：:The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy deci...

journal_title：PharmacoEconomics

authors： Greenberg PE,Arcelus A,Birnbaum HG,Cremieux PY,LeLorier J,Ouellette P,Slavin MB

更新日期：1999-11-01 00:00:00

abstract：:External genital warts (EGW) are a sexually transmitted infection caused by various strains of human papillomavirus (HPV). Several studies have described the direct and indirect costs of EGW, while others have reported on the burden of EGW in terms of the impact on the quality of life (QOL) of patients. The arrival of...

journal_title：PharmacoEconomics

authors： Raymakers AJ,Sadatsafavi M,Marra F,Marra CA

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVE:To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services. METHOD:A stated preference binary choice experiment was used to explore the preferences of members of NICE's Appra...

journal_title：PharmacoEconomics

authors： Tappenden P,Brazier J,Ratcliffe J,Chilcott J

更新日期：2007-01-01 00:00:00

abstract：OBJECTIVE:To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight ...

journal_title：PharmacoEconomics

authors： Maetzel A,Ruof J,Covington M,Wolf A

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that have therapeutic added value in com...

journal_title：PharmacoEconomics

authors： Hoomans T,Severens JL,van der Roer N,Delwel GO

更新日期：2012-03-01 00:00:00